Exclusive live Q&A session

with Bryant McLaughlin, PhD
Chemistry Manufacturing & Controls (CMC) Executive

About the event

In this exclusive live question-and-answer session, you will hear an industry expert's experiences successfully integrating MS-based HCP analysis into their CMC workflow to optimize process development and ensure regulatory compliance.

You will get the opportunity to gain his input on your concerns and queries to gain clarity on the transformative power of this cutting-edge technology.

Join and see how MS technology can revolutionize your approach to characterizing host cell proteins and other impurities.

  • Navigate FDA guidelines confidently 

    Learn about Bryant's experience with the FDA's stance on Mass Spectrometry (MS)-based HCP analysis. Understand how the technology aligns with regulatory expectations, ensuring your strategies are advanced and compliant.

  • Learn from real-world experience

    Discover how your peers have utilized the power of MS-based HCP analysis to overcome challenges similar to those you might be facing.

  • Explore the comparative value of MS-based analysis

    Delve into how MS-based HCP analysis complements traditional methods like ELISAs, including the use of MS for ELISA HCP antibody coverage determination.

  • Bryant McLaughlin, PhD

    For 15 years, Bryant has held CMC executive positions in biotech companies including Genentech, Nektar Therapeutics, and 9 Meters Biopharma, developing mAbs and mAb-like products. His extensive experience includes biologics process and analytical development (including residual host cell protein assay validation), process characterization and validation, and global CMC regulatory writing and strategy.

  • Thomas Kofoed, PhD

    Thomas is a Co-Founder & CEO of Alphalyse. He has 20+ years of management experience in the biotech industry and has developed protein analyses and mass spectrometry methods in the research & development of protein biologics.

  • , ,